A dysfunctional Mo1 glycoprotein is present on a subline of the KG1 acute myelogenous leukemia cell line.
Mo1 is a glycoprotein heterodimer found on the surface of phagocytic cells. By use of monoclonal antibodies directed against various epitopes of the 155 kd alpha-chain of Mo1, two distinct functions of this glycoprotein have been identified. Mo1 serves as the receptor (CR3) for iC3b, one of the breakdown products of the third component of complement, and in addition appears to be involved in promoting cell-cell adhesion of granulocytes. In studies performed with a subline of the acute myelogenous leukemia tumor cell line KG1, we found cells from this subline (KG1m) incapable of iC3b-mediated binding despite these cells having surface Mo1. Five distinct epitopes on Mo1 identifiable on normal cells by a panel of anti-Mo1 alpha-chain monoclonal antibodies (including OKM10, thought to be identical to or close to the iC3b binding site) were equally present on KG1m by indirect immunofluorescence. The electrophoretic mobilities of both the alpha- and beta-chains of Mo1 derived from KG1m were identical to those isolated from normal granulocytes. To determine whether altered receptor mobility or decreased surface density of Mo1 was responsible for the lack of Mo1-related functions, binding to EiC3b of isolated Mo1 derived from KG1m lysate was measured. KG1m-derived Mo1 did not bind to EiC3b when compared with normal granulocyte-derived Mo1, suggesting that the lack of iC3b binding is not secondary to decreased surface receptor number or mobility. This subline of KG1 provides an excellent model for the study of the relationship between surface receptor structure and function.
D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000276:immunology; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D001798:Blood Proteins / Q000235:genetics* / Q000276:immunology; D000001:Calcimycin / Q000494:pharmacology; D002448:Cell Adhesion; D002460:Cell Line; D003179:Complement C3b / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006023:Glycoproteins / Q000235:genetics* / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D016177:Macrophage-1 Antigen; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000235:genetics* / Q000276:immunology; D011951:Receptors, Complement / Q000235:genetics* / Q000276:immunology; D017463:Receptors, Complement 3b
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001798:Blood Proteins; D000939:Epitopes; D006023:Glycoproteins; D016177:Macrophage-1 Antigen; D009363:Neoplasm Proteins; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D000001:Calcimycin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003179:Complement C3b